Pathology of follicular lymphoma
Katsuyoshi Takata, Tomoko Miyata-Takata, Yasuharu Sato, Tadashi Yoshino
Academic Field of Health Sciences
Graduate School of Health Sciences
Follicular lymphoma (FL) is a heterogeneous disease, and there are many different subgroups, such as in terms of age of onset, involved organ (especially extranodal sites such as gastrointestinal tract) and genetic abnormality. Grade 3B is currently regarded as a distinct entity by molecular genetic analyses, but the independence of Grade 3A remains unclear. Variations of clinical course are known in FL. Some cases are very indolent, but others are not. The latter cases show histological transformation to diffuse large B-cell lymphoma (DLBCL) (high-grade transformation) and an aggressive course. Histological transformation to DLBCL is reported to occur in about 30-40% of patients, at a rate of about 3% each year. However, it reaches a plateau at about 16 years, so the stratification of patients in whom transformation would or would not occur is very important for the therapeutic strategy. From genome-wide analysis by next-generation sequencing, EZH2, CREBBP and MLL2, which are histone-modifying genes, have been shown to be frequently mutated in FL and to have an important role in lymphomagenesis. IGH-BCL2 translocation and CREBBP mutations are early events, whereas MLL2 and TNFSFR14 mutations represent late events during disease evolution. In the 2008 WHO classification, three new variants: (1) pediatric follicular lymphoma, (2) primary intestinal follicular lymphoma and (3) in situ follicular lymphoma, are included. Pathologists and clinicians should consider these new developments when deciding on the diagnostic and therapeutic strategy.
Journal of clinical and experimental hematopathology : JCEH
https://doi.org/10.3960/jslrt.54.3
10.3960/jslrt.54.3
Dive into the research topics of 'Pathology of follicular lymphoma'. Together they form a unique fingerprint.
Follicular Lymphoma Medicine & Life Sciences 100%
Pathology Medicine & Life Sciences 51%
Lymphoma, Large B-Cell, Diffuse Medicine & Life Sciences 15%
Pathologists Medicine & Life Sciences 13%
High-Throughput Nucleotide Sequencing Medicine & Life Sciences 12%
Non-Hodgkin's Lymphoma Medicine & Life Sciences 12%
Takata, K., Miyata-Takata, T., Sato, Y., & Yoshino, T. (2014). Pathology of follicular lymphoma. Journal of clinical and experimental hematopathology : JCEH, 54(1), 3-9. https://doi.org/10.3960/jslrt.54.3
Pathology of follicular lymphoma. / Takata, Katsuyoshi; Miyata-Takata, Tomoko; Sato, Yasuharu et al.
In: Journal of clinical and experimental hematopathology : JCEH, Vol. 54, No. 1, 2014, p. 3-9.
Takata, K, Miyata-Takata, T, Sato, Y & Yoshino, T 2014, 'Pathology of follicular lymphoma', Journal of clinical and experimental hematopathology : JCEH, vol. 54, no. 1, pp. 3-9. https://doi.org/10.3960/jslrt.54.3
Takata K, Miyata-Takata T, Sato Y, Yoshino T. Pathology of follicular lymphoma. Journal of clinical and experimental hematopathology : JCEH. 2014;54(1):3-9. doi: 10.3960/jslrt.54.3
Takata, Katsuyoshi ; Miyata-Takata, Tomoko ; Sato, Yasuharu et al. / Pathology of follicular lymphoma. In: Journal of clinical and experimental hematopathology : JCEH. 2014 ; Vol. 54, No. 1. pp. 3-9.
@article{ce8c8adbf0c64d729c83925af8a79d53,
title = "Pathology of follicular lymphoma",
abstract = "Follicular lymphoma (FL) is a heterogeneous disease, and there are many different subgroups, such as in terms of age of onset, involved organ (especially extranodal sites such as gastrointestinal tract) and genetic abnormality. Grade 3B is currently regarded as a distinct entity by molecular genetic analyses, but the independence of Grade 3A remains unclear. Variations of clinical course are known in FL. Some cases are very indolent, but others are not. The latter cases show histological transformation to diffuse large B-cell lymphoma (DLBCL) (high-grade transformation) and an aggressive course. Histological transformation to DLBCL is reported to occur in about 30-40% of patients, at a rate of about 3% each year. However, it reaches a plateau at about 16 years, so the stratification of patients in whom transformation would or would not occur is very important for the therapeutic strategy. From genome-wide analysis by next-generation sequencing, EZH2, CREBBP and MLL2, which are histone-modifying genes, have been shown to be frequently mutated in FL and to have an important role in lymphomagenesis. IGH-BCL2 translocation and CREBBP mutations are early events, whereas MLL2 and TNFSFR14 mutations represent late events during disease evolution. In the 2008 WHO classification, three new variants: (1) pediatric follicular lymphoma, (2) primary intestinal follicular lymphoma and (3) in situ follicular lymphoma, are included. Pathologists and clinicians should consider these new developments when deciding on the diagnostic and therapeutic strategy.",
author = "Katsuyoshi Takata and Tomoko Miyata-Takata and Yasuharu Sato and Tadashi Yoshino",
doi = "10.3960/jslrt.54.3",
journal = "Journal of clinical and experimental hematopathology : JCEH",
publisher = "Nihon Rinpa Monaikei Gakkai",
T1 - Pathology of follicular lymphoma
AU - Takata, Katsuyoshi
AU - Miyata-Takata, Tomoko
AU - Sato, Yasuharu
AU - Yoshino, Tadashi
N2 - Follicular lymphoma (FL) is a heterogeneous disease, and there are many different subgroups, such as in terms of age of onset, involved organ (especially extranodal sites such as gastrointestinal tract) and genetic abnormality. Grade 3B is currently regarded as a distinct entity by molecular genetic analyses, but the independence of Grade 3A remains unclear. Variations of clinical course are known in FL. Some cases are very indolent, but others are not. The latter cases show histological transformation to diffuse large B-cell lymphoma (DLBCL) (high-grade transformation) and an aggressive course. Histological transformation to DLBCL is reported to occur in about 30-40% of patients, at a rate of about 3% each year. However, it reaches a plateau at about 16 years, so the stratification of patients in whom transformation would or would not occur is very important for the therapeutic strategy. From genome-wide analysis by next-generation sequencing, EZH2, CREBBP and MLL2, which are histone-modifying genes, have been shown to be frequently mutated in FL and to have an important role in lymphomagenesis. IGH-BCL2 translocation and CREBBP mutations are early events, whereas MLL2 and TNFSFR14 mutations represent late events during disease evolution. In the 2008 WHO classification, three new variants: (1) pediatric follicular lymphoma, (2) primary intestinal follicular lymphoma and (3) in situ follicular lymphoma, are included. Pathologists and clinicians should consider these new developments when deciding on the diagnostic and therapeutic strategy.
AB - Follicular lymphoma (FL) is a heterogeneous disease, and there are many different subgroups, such as in terms of age of onset, involved organ (especially extranodal sites such as gastrointestinal tract) and genetic abnormality. Grade 3B is currently regarded as a distinct entity by molecular genetic analyses, but the independence of Grade 3A remains unclear. Variations of clinical course are known in FL. Some cases are very indolent, but others are not. The latter cases show histological transformation to diffuse large B-cell lymphoma (DLBCL) (high-grade transformation) and an aggressive course. Histological transformation to DLBCL is reported to occur in about 30-40% of patients, at a rate of about 3% each year. However, it reaches a plateau at about 16 years, so the stratification of patients in whom transformation would or would not occur is very important for the therapeutic strategy. From genome-wide analysis by next-generation sequencing, EZH2, CREBBP and MLL2, which are histone-modifying genes, have been shown to be frequently mutated in FL and to have an important role in lymphomagenesis. IGH-BCL2 translocation and CREBBP mutations are early events, whereas MLL2 and TNFSFR14 mutations represent late events during disease evolution. In the 2008 WHO classification, three new variants: (1) pediatric follicular lymphoma, (2) primary intestinal follicular lymphoma and (3) in situ follicular lymphoma, are included. Pathologists and clinicians should consider these new developments when deciding on the diagnostic and therapeutic strategy.
U2 - 10.3960/jslrt.54.3
DO - 10.3960/jslrt.54.3
JO - Journal of clinical and experimental hematopathology : JCEH
JF - Journal of clinical and experimental hematopathology : JCEH